Introduction to the EMBARK Approach
EMBARK Psychedelic Therapy for Depression April 23, 2024 DOI: 10.1093/9780197762622.003.0003 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper Peer reviewed |
|---|---|
| Key points | The authors propose EMBARK, a flexible six-domain framework for psychedelic-assisted therapy, as a response to gaps they identify in prior PAT models—including limited attention to the body, therapeutic relationship, spiritual experience counseling, and ethics—and argue that efficacious treatment is ethical treatment, grounded in four cornerstones of care. |
Abstract
AbstractChapter 2 provides a rationale for the EMBARK approach, a therapeutic framework for administering psychedelic medicines. The authors assess previous PAT models, highlighting their strengths and shortcomings. They identify gaps in areas such as attentiveness to the body, attending to the therapeutic relationship, counseling for spiritual experiences, and ethical considerations. The chapter also discusses the challenges associated with prior PAT models, including (a) underdeveloped therapeutic frames and (b) single EBT-based PAT approaches. The EMBARK approach is presented as a solution to these challenges, offering a flexible and adaptable model for psychedelic therapy. EMBARK is an acronym, and its six clinical domains are outlined: Existential–Spiritual, Mindfulness, Body-Aware, Affective–Cognitive, Relational, and Keeping Momentum. EMBARK is also built upon a foundational belief that efficacious treatment is ethical treatment. It is built upon four cornerstones of care: Trauma-Informed Care, Culturally Competent Care, Ethically Rigorous Care, and Collective care.
Citations in the library
Cites 217
- Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Journal of Psychopharmacology November 30, 2016
- Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Journal of Psychopharmacology November 30, 2016
- Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance Psychopharmacology July 7, 2006
- Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. The Lancet Psychiatry May 17, 2016
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
and 212 more in the library